Country Report: Taiwan - Pharmaceutical Executive


Country Report: Taiwan

Pharmaceutical Executive


Biotechnology Industry Revenues, 2004–2012
The Biotechnology & Pharmaceutical Industries Promotion Office (BPIPO) reports that total revenues for the industry have more than doubled between 2004 and 2012, to USD 8.88 billion. Lee attributes much of the difference to the newcomers, founded amid a wave of investment that began in the early 1990s. After what Lee calls an "ungraceful" development period, these companies have now surpassed Taiwan's "old guard"—large, established players that sold generics locally for decades—in terms of innovation and internationalization.

Excellent turnout at BioTaiwan
Wang says the industry is in the latter end of its incubation stage. Looking ahead, Taiwan Inc.'s pipeline looks great: 17 compounds in Phase I, 73 in Phase II and III, and 6 at the NDA stage (BPIPO, April 2013).

Government support: a breakdown
Meanwhile, the Economic Cooperation Framework Agreement (ECFA), a preferential trade pact between China and Taiwan signed in 2010, has lowered trade barriers and opened the door for broader collaboration with a country that IMS estimates will become the world's second largest pharma market by 2015. "If Taiwanese companies develop a new molecule for a condition with high prevalence in Asia, why not benefit a larger population?," DCB's Lee points out.

Products make the platform
Investors smell an opportunity. "In the past," Lee says, "we were missing a crucial element of our ecosystem: financing. Now, because of the health of our capital market, venture capitalists are quite willing to come on board because they see an exit: sell the shares when companies float their stock on the public market. If Initial Public Offerings (IPOs) weren't so feasible in Taiwan at the moment, investors would be very reluctant to participate in the long-term play that is biotech."


blog comments powered by Disqus

Source: Pharmaceutical Executive,
Click here